WORTZMAN MARILYN E 4

4 · Transcept Pharmaceuticals Inc · Filed Mar 20, 2012

Form 4

Period: 2012-03-19

VP, Finance

Transactions

Sale
Common Stock
2012-03-19$10.00/sh−4,027$40,270→ 217 total
Sale
Common Stock
2012-03-19$10.00/sh−4,600$46,000→ 217 total
Sale
Common Stock
2012-03-19$10.00/sh−573$5,730→ 217 total
Exercise/Conversion
Common Stock
2012-03-19$1.77/sh+4,027$7,123→ 4,244 total
Exercise/Conversion
Common Stock
2012-03-19$2.12/sh+573$1,216→ 790 total
Exercise/Conversion
Common Stock
2012-03-19$4.14/sh+4,600$19,044→ 4,817 total
Exercise/Conversion
Employee Stock Option (right to buy)
2012-03-19−4,027→ 0 total
Exercise: $1.77Exp: 2017-04-04→ Common Stock (4,027 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2012-03-19−573→ 5,081 total
Exercise: $2.12Exp: 2017-08-22→ Common Stock (573 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2012-03-19−4,600→ 15,400 total
Exercise: $4.14Exp: 2019-02-12→ Common Stock (4,600 underlying)

Footnotes (4)

[F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 17, 2011.
[F2]One-fourth of the shares subject to the option vested on March 16, 2008 and one forty-eighth of the shares shall vest monthly thereafter.
[F3]One-fourth of the shares subject to the option vested on August 22, 2008 and one forty-eighth of the shares shall vest monthly thereafter.
[F4]The option vests in forty-eight equal monthly installments beginning March 12, 2009.

Documents

1 file